Daily Archives: March 25, 2020

From the moment she took over our screens when Stranger Things first hit Netflix, Millie Bobby Browns hair has captured our attention. After the initial season aired, Brown shared a video on Instagram of the now infamous head shave. The Stranger Things co-creators Matt and Ross Duffer recorded the event on their phones and captured the very moment when Millie Bobby Brown transformed into Eleven. She spoke positively about shaving her head and displayed wisdom well beyond her years when she claimed she wanted to do it to show other young girls that we are more than our hair.

Since then, Brown has continued to showcase her hair transformation by sharing her hair journey with all of us on her Instagram profile. Were highlighting all of the lengths, colors, and styles the star has tried on as she continues to grow out her locks and embrace a new chapter of her life.

Here is the original post:

The Evolution of Millie Bobby Brown's Hair - Revelist

Lets start up with the current stock price of Sorrento Therapeutics, Inc. (SRNE), which is $2.07 to be very precise. The Stock rose vividly during the last session to $2.2 after opening rate of $2.1 while the lowest price it went was recorded $2.05 before closing at $2.05.

Sorrento Therapeutics, Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $5.76 on 03/26/19, with the lowest value was $1.39 for the same time period, recorded on 10/11/19.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Sorrento Therapeutics, Inc. shares are logging -64.06% during the 52-week period from high price, and 48.92% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $1.39 and $5.76.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 6.09 million for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Sorrento Therapeutics, Inc. (SRNE) recorded performance in the market was -38.76%, having the revenues showcasing -38.94% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 329.23M, as it employees total of 310 workers.

During the last month, 1 analysts gave the Sorrento Therapeutics, Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 2.86, with a change in the price was noted +0.52. In a similar fashion, Sorrento Therapeutics, Inc. posted a movement of +33.55% for the period of last 100 days, recording 6,472,079 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for SRNE is recording 2.99 at the time of this writing. In addition, long term Debt to Equity ratio is set at 2.53.

Raw Stochastic average of Sorrento Therapeutics, Inc. in the period of last 50 days is set at 17.69%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 55.91%. In the last 20 days, the companys Stochastic %K was 52.74% and its Stochastic %D was recorded 39.21%.

Considering, the past performance of Sorrento Therapeutics, Inc., multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be encouraging, given the fact the metric is recording -38.76%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -7.17%, alongside a downfall of -61.45% for the period of the last 12 months. The shares increased approximately by 19.96% in the 7-day charts and went up by 16.95% in the period of the last 30 days. Common stock shares were lifted by -38.94% during last recorded quarter.

See the original post here:

Sorrento Therapeutics, Inc. (SRNE) is primed for evolution with the beta value of 2.63 - The InvestChronicle

Posted by Shradhdha Das

Marvel struck gold with Iron Man and began to capitalize on the superhero genre in 2008. Pepper Potts was introduced in the first Iron Man as Tony Starks love interest she worries over his health and safety, later taking over Stark Industries. She exists completely in his context and never seems important to the plot.

The Black Widow movie was announced only after the character sacrificed herself in Endgame in 2019. DC and Warner Bros Wonder Woman was the definitive game changer that led to this move. Released in 2017, following a renewed feminist movement across the world in the face of right wing governments, Wonder Woman was an instant success. Feminists and film critics lauded the film for its portrayal of Diana Prince. The film is an origin story that explores how Diana is introduced to mans world and how she ultimately saves it from itself. She values her femininity and her mission to save the world is ultimately driven (and won) by empathy and kindness.

In the Marvel Cinematic Universe, Taika Waititis Thor: Ragnarok introduced us to Valkyrie, whose only likeable trait was that she could kick ass in a fight. A complete opposite of Diana cynical instead of hopeful, a mercenary instead of a saviour, disillusioned instead of amazed at the world around her and yet, she is a superhero. Where Diana was perfect and good, Valkyrie is messy and selfish and its liberating to watch both of them have complete control over their stories on screen.

Where Diana was perfect and good, Valkyrie is messy and selfish and its liberating to watch both of them have complete control over their stories on screen.

In a bid to appeal to increasingly diverse global audiences, Marvel Studios announced Black Panther. The women of Black Panther were layered and multi-dimensional Shuri is a genius scientist/princess, Nakia is a radical secret agent, Ramonda is the grieving but strong queen and Okoye is the fiercely loyal chief of the kings guard. Their character arcs are never hindered by their respective relationships with the hero. Black Panther set a new benchmark for representation.

Brie Larsons political activism and Infinity Wars post credits scene leading into Captain Marvel, made the movie highly anticipated. When it finally released, the story it told was a distinctly female one. Carol Danvers is constantly told to rein her powers in, to not let her anger fuel her actions. She struggles with her emotions and instincts, not trusting them and believing that theyre getting in her way. This has never been the case with any of the male Avengers they simply acquire their powers and go trigger happy with them.

But Carol doesnt get this luxury, and its frustrating to watch. Where their anger is righteous and just, hers is dangerous and unwelcome. Shes the most powerful character in the MCU, and yet shes the only one forced to fight with one hand tied behind her back. Her memory is erased and shes then used as a weapon on the wrong side of the war her agency is stripped in a manner that is jarringly reflective of the world we live in. The definitive moment of the film is when she spares her mentor-turned-nemesis, but not out of the goodness of her heart.

Also read: Its About Time We Had A Female Indian Superhero!

I dont need to prove anything to you she says, rising above male validation, quite literally. The film is a remarkably brazen and timely rejection of the many ways in which male perspective shapes female lives. It made a billion dollars at the domestic box office, despite a targeted trolling effort which significantly reduced its score on IMDb and Rotten Tomatoes.

DC made history with the highly entertaining and blessedly free of male gaze Birds of Prey. Harley Quinn has never been a superhero, let alone a feminist one, but Margot Robbies portrayal of her in Birds of Prey is hilarious, powerful and downright insane. It does away with all the unnecessary hyper-sexualisation and lets the characters be imperfect.

DC made history with the highly entertaining and blessedly free of male gaze Birds of Prey. Harley Quinn has never been a superhero, let alone a feminist one, but Margot Robbies portrayal of her in Birds of Prey is hilarious, powerful and downright insane. It does away with all the unnecessary hyper-sexualisation and lets the characters be imperfect. They are not glorified, a phenomenon that has become sort of an occupational hazard with strong female characters across genres.

While representation seems to be heading in the right direction, it has not been an easy ride. All of these movies have been heavily criticised by misogynists across the world. There are versions of Avengers: Endgame on YouTube in which all scenes featuring women have been edited out.The actresses have been ruthlessly trolled online, sat across sexist interviewers who are only interested in tight costumes and overtly sexualised by fans and filmmakers alike.

The world of superheroes has always been unfair to women, just like ours. The purpose of stories is to make a variety of audiences empathise with the protagonists and in turn, empathise with the people around them. For ages, these protagonists have been men.

Also read: Captain Marvel: The Female Superhero We Deserve

Its 2020 but people still dont seem to understand that empathising with a woman wont hurt anyone.

Shradhdha is a journalism student, pop culture lover and feminist-in-progress whos hated universally by cats. You can find her on Twitter and Instagram.

Featured Image Source: Mirror

Original post:

From Catsuits To Captains The Evolution Of Women In Superhero Films - Feminism in India

Lets start up with the current stock price of Sabra Health Care REIT, Inc. (SBRA), which is $10.22 to be very precise. The Stock rose vividly during the last session to $10.35 after opening rate of $10.01 while the lowest price it went was recorded $9.48 before closing at $9.37.

Sabra Health Care REIT, Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $24.95 on 10/31/19, with the lowest value was $5.55 for the same time period, recorded on 03/18/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Sabra Health Care REIT, Inc. shares are logging -59.04% during the 52-week period from high price, and 84.31% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $5.55 and $24.95.

The companys shares, operating in the sector of financial managed to top a trading volume set approximately around 4 million for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Sabra Health Care REIT, Inc. (SBRA) recorded performance in the market was -52.11%, having the revenues showcasing -52.18% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 1.55B, as it employees total of 34 workers.

During the last month, 3 analysts gave the Sabra Health Care REIT, Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 9 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 2 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 20.35, with a change in the price was noted -13.59. In a similar fashion, Sabra Health Care REIT, Inc. posted a movement of -57.08% for the period of last 100 days, recording 2,562,886 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for SBRA is recording 0.69 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.69.

Raw Stochastic average of Sabra Health Care REIT, Inc. in the period of last 50 days is set at 27.50%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 28.88%. In the last 20 days, the companys Stochastic %K was 24.14% and its Stochastic %D was recorded 18.68%.

Bearing in mind the latest performance of Sabra Health Care REIT, Inc., several moving trends are noted. Year-to-date Price performance of the companys stock appears to be encouraging, given the fact the metric is recording -52.11%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -54.68%, alongside a downfall of -45.84% for the period of the last 12 months. The shares sunk approximately by in the 7-day charts and went up by 37.92% in the period of the last 30 days. Common stock shares were lifted by -52.18% during last recorded quarter.

Read more:

Sabra Health Care REIT, Inc. (SBRA) is primed for evolution with the beta value of 1.77 - The InvestChronicle